- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07716176
Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Docetaxel Plus Cyclophosphamide (ADDC Ⅱ)
Auricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Docetaxel Combined With Cyclophosphamide in Breast Cancer Adjuvant Chemotherapy
This study aims to evaluate whether the preventive and suppressive effects of auricular point stimulation combined with dexamethasone on nausea and vomiting induced by the docetaxel plus cyclophosphamide regimen are non-inferior to the standard antiemetic regimen. Additionally, it will assess patients' appetite, gastrointestinal function, and other related indicators, and explore the significant role of integrated traditional Chinese medicine and Western medicine interventions in improving patients' quality of life during chemotherapy, thereby providing a clinical reference for optimizing the management of adverse reactions of this chemotherapy regimen.
The main questions it aims to answer are: Whether the preventive and suppressive effects of auricular point stimulation combined with dexamethasone on nausea and vomiting induced by the docetaxel plus cyclophosphamide regimen are non-inferior to the standard antiemetic regimen? In comparison with a standard pharmacologic antiemetic regimen, does auricular point stimulation plus dexamethasone effectively reduce the incidence of appetite loss, weakened or disordered gastrointestinal function, and other uncomfortable conditions?
Breast cancer patients receiving adjuvant chemotherapy with the docetaxel plus cyclophosphamide regimen after surgery will be randomly assigned in a 1:1 ratio to either the auricular point stimulation group or the standard pharmacologic antiemetic regimen group. Patients in the auricular point stimulation group will: Receive auricular acupressure with bean seeds on specific points of one ear, plus intravenous injection of dexamethasone as a preventive antiemetic treatment within half an hour before chemotherapy. Starting from the day of chemotherapy (Day 1) to the following five days (Day 1-Day 5), provide regular stimulation at the acupressure points daily by themselves according to the protocol provided in this trial. Record their nausea and vomiting status, appetite, and gastrointestinal function-related symptomatic indicators from Day 1 to Day 5. Oral antiemetics are also prepared. If nausea and vomiting are significant or the patient feels the need, they may be temporarily administered as an adjunct. Patients in the standard pharmacologic antiemetic regimen group will: Receive the standard pharmacologic antiemetic regimen chosen by their physicians according to clinical guidelines.
Přehled studie
Postavení
Detailní popis
Docetaxel combined with cyclophosphamide is one of the most commonly used chemotherapy regimens for postoperative adjuvant treatment of breast cancer. While it improves patients' survival rate, it is accompanied by certain gastrointestinal adverse reactions, among which chemotherapy-induced nausea and vomiting (CINV) is relatively common, with an incidence rate ranging from 16% to 54%. The vast majority of cases occur on the day of medication and within 4 days thereafter. This regimen is defined as a chemotherapy regimen with low to moderate emetogenic risk in current clinical guidelines. The recommended preventive antiemetic strategy usually consists of glucocorticoids (e.g., dexamethasone) combined with 5-HT3 receptor antagonists (e.g., ondansetron, palonosetron, etc.). It can be strengthened with NK1 receptor antagonists (e.g., fosaprepitant, aprepitant) and the antipsychotic olanzapine, depending on clinical circumstances. However, in clinical practice, many patients experience drug-related gastrointestinal adverse reactions such as anorexia, abdominal distension, constipation, and diarrhea due to receiving high-intensity antiemetic therapy. Studies have shown that the incidence of constipation in chemotherapy patients treated with palonosetron approximately doubles. The high-intensity use of antiemetic drugs seriously impairs patients' gastrointestinal function and quality of life, and even affects their treatment compliance. Therefore, how to effectively prevent CINV while minimizing the side effects caused by antiemetic therapy itself has become a practical issue that medical staff need to pay urgent attention to. Auricular point pressotherapy is a traditional Chinese medicine (TCM) external therapy. It involves accurately pasting Vaccaria seeds on corresponding auricular points with adhesive tapes and stimulating the points through moderate pressing to regulate physical functions and treat diseases. According to TCM theory, the ear is closely connected to the internal organs and meridians of the human body, and all twelve meridians are directly or indirectly linked to the ear. Auricular point pressotherapy can unblock meridians and balance yin and yang by stimulating corresponding auricular points, thereby alleviating CINV and other adverse reactions. It is an economical, non-invasive, and low-side-effect natural therapy. Meanwhile, auricular point pressotherapy can effectively improve gastrointestinal function, thus significantly reducing gastrointestinal dysfunction caused by chemotherapy and antiemetic drugs, such as anorexia, abdominal distension, constipation, and diarrhea. Our team summarized the relevant data of patients who voluntarily received auricular point pressotherapy for antiemesis previously. The results showed that among breast cancer patients who received docetaxel combined with cyclophosphamide for postoperative adjuvant chemotherapy, 100% of those treated with auricular point pressotherapy plus dexamethasone did not experience grade 2 or above (including grade 2) nausea and had no vomiting on the day of medication and within 3 days thereafter.
Based on the above theoretical and practical basis, this study intends to evaluate whether the preventive and suppressive effects of auricular point stimulation combined with dexamethasone on the CINV induced by the docetaxel plus cyclophosphamide regimen are non-inferior to the standard antiemetic regimen. Additionally, it will assess patients' appetite, gastrointestinal function, and other related indicators, and explore the significant role of integrated traditional Chinese medicine and Western medicine interventions in improving patients' quality of life during chemotherapy, thereby providing a clinical reference for optimizing the management of adverse reactions of this chemotherapy regimen.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 3
Kontakty a umístění
Studijní kontakt
- Jméno: Juan Wang
- Telefonní číslo: 8617816190946
- E-mail: wangjuan.happy@hotmail.com
Studijní místa
-
-
-
Hangzhou, Čína
- Nábor
- Second Affiliated Hospital of Zhejiang University School of Medicine
-
Kontakt:
- Juan Wang
- Telefonní číslo: 8617816190946
- E-mail: wangjuan.happy@hotmail.com
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Popis
Inclusion Criteria:
- Patients must meet the following inclusion criteria for the study:* Age ≥ 18 years and ≤ 85 years* After a radical mastectomy, further postoperative adjuvant chemotherapy with docetaxel combined with cyclophosphamide regimen is required.* ECOG performance status score of 0-2.* Normal hematological function (platelet count > 80×10⁹/L; white blood cell count > 3×10⁹/L; neutrophil count > 1.5×10⁹/L).* Serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), and transaminase ≤ 5 times the ULN.* No ascites, no gastrointestinal obstruction, normal coagulation function, and serum albumin ≥ 30g/L.* Child-Pugh classification of liver function is Grade A.* Serum creatinine < ULN, or calculated creatinine clearance rate > 50ml/min.
Exclusion Criteria:
- Patients who meet any of the following criteria will be excluded from the study: * Local inflammation or infection of the auricle* Bleeding tendency or coagulation disorders* Severe ascites* Gastrointestinal obstruction* Hypertensive crisis or hypertensive encephalopathy* Severe uncontrolled systemic complications such as infection or diabetes mellitus* Clinically severe cardiovascular diseases, including cerebrovascular accident (within 6 months before enrollment), myocardial infarction (within 6 months before enrollment), hypertension that is not well-controlled despite appropriate medication, unstable angina pectoris, congestive heart failure (NYHA Class 2-4), and cardiac arrhythmias requiring drug treatment* A history of or physical examination findings indicating central nervous system diseases (e.g., primary brain tumor, epilepsy uncontrolled by standard treatment, any history of brain metastasis or stroke)* Hypersensitivity to any drugs used in the study* Pregnant or lactating women* Presence of any other diseases, functional impairment caused by metastatic lesions, or suspicious disorders identified during physical examination, which suggest contraindications to the study drugs or place the patient at high risk of treatment-related complications* Inability or unwillingness to comply with the study protocol.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Aktivní komparátor: Standard pharmacologic antiemetic regimen group
Patients in the standard pharmacologic antiemetic regimen group will receive the standard pharmacologic antiemetic regimen chosen by their physicians according to clinical guidelines and patients' actual conditions.
|
Receive the standard pharmacologic antiemetic regimen chosen by their physicians according to clinical guidelines and patients' actual conditions, including dexamethasone ± 5-HT3 receptor inhibitor ± NK1 receptor inhibitor ± Olanzapine.
|
|
Experimentální: Auricular point stimulation group
For breast cancer patients who will receive docetaxel combined with cyclophosphamide for postoperative adjuvant chemotherapy, preventive antiemetic treatment consisting of unilateral auricular point stimulation at specific acupoints and dexamethasone will be administered within 30 minutes before chemotherapy.
Auricular acupoint stimulation is performed by adhering Vaccaria seeds to specific points with adhesive tape and applying moderate pressure until a certain level of soreness is elicited.
Vaccaria seeds are kept on the ear from the day of chemotherapy (Day 1) until the end of Day 5.
|
On the day of chemotherapy (Day 1): within half an hour before chemotherapy, administer auricular acupressure on one ear (stimulating the stomach, cardia, and brainstem acupoints for 5 minutes each) along with an intravenous push of 5 mg dexamethasone.
From the day of chemotherapy (Day 1) to the following five days (Day 1-Day 5): Stimulate each acupoint once in the morning, at noon, and in the evening, for 5 minutes each time.
If nausea or vomiting occurs, immediately apply additional stimulation for 5 minutes as a temporary measure.
Oral antiemetics should be prepared and may be used temporarily if nausea and vomiting are significant and the patient feels the need.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Podíl pacientů pociťujících nevolnost hodnocený podle NIC-CTC AE4.0
Časové okno: od dne chemoterapie (1. den) do konce 5. dne
|
Účastníci budou požádáni, aby vyplnili dotazník, který zaznamená, zda se vyskytne nevolnost.
Pokud se nevolnost vyskytne, měl by být zaznamenán její stupeň podle NIC-CTC AE4.0.
|
od dne chemoterapie (1. den) do konce 5. dne
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Podíl pacientů trpících zvracením hodnocený dle NIC-CTC AE4.0
Časové okno: od dne chemoterapie (Den 1) do konce Dne 5
|
Účastníci budou požádáni o vyplnění dotazníku, aby se zaznamenalo, zda se vyskytne zvracení.
Pokud ke zvracení dojde, měl by být zaznamenán jeho stupeň podle NIC-CTC AE4.0.
|
od dne chemoterapie (Den 1) do konce Dne 5
|
|
Podíl pacientů vyžadujících další antiemetika
Časové okno: od dne chemoterapie (den 1) do dne 5
|
od dne chemoterapie (den 1) do dne 5
|
Další výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Podíl pacientů s nežádoucími účinky souvisejícími s chemoterapií hodnocenými podle CTCAE v4.0
Časové okno: od dne chemoterapie (1. den) do 5. dne
|
od dne chemoterapie (1. den) do 5. dne
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Studijní židle: Juan Wang, Second Affiliated Hospital, School of Medicine, Zhejiang University
Publikace a užitečné odkazy
Obecné publikace
- Kimura S, Hosoya K, Ogata K, Furuno T, Sogawa R, Takeuchi K, Tasaki M, Kawaguchi A, Nishioka A, Sueoka-Aragane N, Noshiro H, Kuratomi Y, Yokoyama M, Noguchi M, Anzai K, Yamashita Y, Kimura S, Irie H. Severity of constipation related to palonosetron during first-line chemotherapy: a retrospective observational study. Support Care Cancer. 2021 Aug;29(8):4723-4732. doi: 10.1007/s00520-021-06023-0. Epub 2021 Jan 29.
- Llombart-Cussac A, Ramos M, Dalmau E, Garcia-Saenz JA, Gonzalez-Farre X, Murillo L, Calvo L, Morales S, Caranana V, Gonzalez A, Fernandez-Morales LA, Moreno F, Casas MI, Angulo Mdel M, Camara MC, Garcia-Mace AI, Carrasco E, Jara-Sanchez C. Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study. Eur J Cancer. 2016 May;58:122-9. doi: 10.1016/j.ejca.2016.01.015. Epub 2016 Mar 17.
- Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, Pippen JE, Bordelon JH, Kirby R, Sandbach J, Hyman WJ, Khandelwal P, Negron AG, Richards DA, Anthony SP, Mennel RG, Boehm KA, Meyer WG, Asmar L. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006 Dec 1;24(34):5381-7. doi: 10.1200/JCO.2006.06.5391.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 20251945
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Auricular point stimulation plus dexamethasone
-
Max-Planck-Institute of PsychiatryNáborDeprese | Bipolární poruchaNěmecko
-
Wayne State UniversityZatím nenabírámePTSD – posttraumatická stresová poruchaSpojené státy
-
Gaziler Physical Medicine and Rehabilitation Education...NáborPoranění míchy (SCI)Krocan
-
Hatice Betigul MeralDokončenoChronická bolest | Fibromyalgie (FM)Turecko (Türkiye)
-
Electronic Waveform LabZatím nenabírámeChirurgická oprava roztržení rotátorové manžetySpojené státy
-
The University of Texas Health Science Center,...NáborBolest kloubů | Chronická bolest kolen | Chronická bolest (záda / šíje) | Léčba chronické bolestiSpojené státy
-
Second Affiliated Hospital, School of Medicine,...NáborNevolnost a zvracení způsobené chemoterapiíČína
-
Second Affiliated Hospital, School of Medicine,...NáborNevolnost a zvracení způsobené trastuzumabem deruxtecanemČína
-
Second Affiliated Hospital, School of Medicine,...NáborNevolnost a zvracení způsobené chemoterapiíČína
-
Zhejiang Cancer HospitalDokončenoDifúzní velký B-buněčný lymfom (DLBCL) | Intratekální chemoterapieČína